ArticleThe oncologist2025
Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHLX02 (Zercepac®) is the first trastuzumab biosimilar manufactured in China. This study presents the first real-world comparison of HLX02 with reference trastuzumab (RTZ) plus pertuzumab and chemotherapy as the first-line treatment for HER2-positive metastatic breast cancer (MBC) patients.
methodsMedical data of patients with HER2-positive MBC who received HLX02 or RTZ, both combined with pertuzumab and various chemotherapies as the first-line therapy at Beijing Cancer Hospital from January 2019 to August 2023 were reviewed retrospectively. The survival outcomes, efficacy, and adverse events were analyzed.
resultsIn total, 118 patients were included in this study retrospectively, among whom 66 patients received RTZ and 52 received HLX02. No significant difference was observed in progression-free survival (PFS) between the groups (median PFS: 22.0 months for RTZ vs. 19.0 months for HLX02, P = .832). Additionally, the objective response rate, disease control rate, and safety profiles were similar across both groups. Of all 118 patients, 20 (16.9%) patients experienced progression in the central nervous system (CNS), with a median time to CNS progression of 15.0 months (95% confidence interval, CI, 12.8-17.2).
conclusionThe real-world data suggested that both HLX02 and RTZ, when combined with pertuzumab and various chemotherapy regimens, offer comparable efficacy and safety as first-line treatments for HER2-positive advanced breast cancer patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.